Pretargeted Imaging for In Vivo Assessment of ASO Therapy Delivery in Alzheimer’s Disease
Pretargeted Imaging for In Vivo Assessment of ASO Therapy Delivery in Alzheimer’s Disease
About this item
Full title
Author / Creator
Cook, Brendon E , Pickel, Thomas C , Amatruda, Mario , Zhang, Qize , Nag, Sangram , Bolduc, Phillipe , Beshr, Rouaa , Morén, Anton Forsberg , Muste, Cathy , Datta, Prodip , Ochniewicz, Piotr , Meynaq, Yasir Khani , DuBois, Jonathan M. , Klein, Stephanie K , Halldin, Christer , Passamonti, Luca and Kaliszczak, Maciej
Publisher
Hoboken: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Background
Intrathecally (IT) delivered antisense oligonucleotides (ASOs) are promising therapies that can reduce tau pathology in Alzheimer’s Disease (AD). However, current plasma and CSF sampling methods to estimate brain tissue exposure of ASOs are inherently limited, hampering ASO clinical developmental plans. We developed the PET tracer [18...
Alternative Titles
Full title
Pretargeted Imaging for In Vivo Assessment of ASO Therapy Delivery in Alzheimer’s Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11712871
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11712871
Other Identifiers
ISSN
1552-5260
E-ISSN
1552-5279
DOI
10.1002/alz.093694
